InMed Pharmaceuticals (INM) Cash & Equivalents: 2021-2025
Historic Cash & Equivalents for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to $9.4 million.
- InMed Pharmaceuticals' Cash & Equivalents rose 68.37% to $9.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.4 million, marking a year-over-year increase of 68.37%. This contributed to the annual value of $11.1 million for FY2025, which is 68.54% up from last year.
- InMed Pharmaceuticals' Cash & Equivalents amounted to $9.4 million in Q3 2025, which was down 15.13% from $11.1 million recorded in Q2 2025.
- Over the past 5 years, InMed Pharmaceuticals' Cash & Equivalents peaked at $15.3 million during Q3 2021, and registered a low of $3.5 million during Q4 2024.
- In the last 3 years, InMed Pharmaceuticals' Cash & Equivalents had a median value of $7.6 million in 2024 and averaged $7.6 million.
- In the last 5 years, InMed Pharmaceuticals' Cash & Equivalents plummeted by 63.29% in 2024 and then surged by 68.54% in 2025.
- InMed Pharmaceuticals' Cash & Equivalents (Quarterly) stood at $11.3 million in 2021, then climbed by 1.53% to $11.5 million in 2022, then fell by 16.74% to $9.5 million in 2023, then plummeted by 63.29% to $3.5 million in 2024, then soared by 68.37% to $9.4 million in 2025.
- Its last three reported values are $9.4 million in Q3 2025, $11.1 million for Q2 2025, and $4.7 million during Q1 2025.